Search results
Showing 1051 to 1100 of 2008 results for news
Day-to-day decision making is the responsibility of NICE's executive team.
This guideline covers how to improve services for people aged 14 and above who have been diagnosed as having coexisting severe mental illness and substance misuse. The aim is to provide a range of coordinated services that address people’s wider health and social care needs, as well as other issues such as employment and housing.
stimulation. Outcomes should include ejection fraction, oxygen consumption, New York Heart Association classification and...
intending to collect clinical data from people having treatment with the new generation of hepatitis C virus treatments. NICE agreed...
Cipaglucosidase alfa with miglustat for treating late-onset Pompe disease (TA912)
Evidence-based recommendations on cipaglucosidase alfa (Pombiliti) with miglustat (Opfolda) for treating late-onset Pompe disease in adults.
Evidence-based recommendations on pembrolizumab (Keytruda) for relapsed or refractory classical Hodgkin lymphoma in people 3 years and over.
Tobacco: preventing uptake, promoting quitting and treating dependence (NG209)
This guideline covers support to stop smoking for everyone aged 12 and over, and help to reduce people's harm from smoking if they are not ready to stop in one go. It also covers ways to prevent children, young people and young adults aged 24 and under from taking up smoking.
Faltering growth: recognition and management of faltering growth in children (NG75)
This guideline covers recognition, assessment and monitoring of faltering growth in infants and children. It includes a definition of growth thresholds for concern and identifying the risk factors for, and possible causes of, faltering growth. It also covers interventions, when to refer, service design, and information and support.
This guideline covers managing cataracts in adults aged 18 and over. It aims to improve care before, during and after cataract surgery by optimising service organisation, referral and surgical management, and reducing complications. It further aims to improve the availability of information for people with cataracts before, during and after cataract surgery.
Constipation in children and young people: diagnosis and management (CG99)
This guideline covers diagnosing and managing constipation in children and young people up to 18. It provides strategies to support the early identification and timely, effective treatment of constipation which will help improve outcomes for patients. It does not cover constipation caused by a specific condition.
NICE has developed a medtech innovation briefing (MIB) on Smart One for measuring lung function .
Evidence-based recommendations on KardiaMobile for detecting atrial fibrillation.
include quality of life using relevant and validated measures, including the New York Heart Association classification, survival and the...
diabetic foot problems was limited and inconclusive. It is proposed that new interventions are developed that target psychological and...
How can the effectiveness of workplace health policies and programmes be measured?
consider the effects of staged interventions (such as training line managers in new practices, assessing uptake and implementation, and...
Summary of the evidence on avanafil for treating erectile dysfunction to inform local NHS planning and decision-making
strategies). The committee were unaware of existing questionnaires and so new research should develop and test questionnaires for...
needed to prevent potential health deterioration and quickly identify any new health-related conditions. Source guidance details Comes...
capture long term outcomes including changes to current lymphoedema or any new onset lymphoedema in other part of the limb. Outcomes for...
NICE has developed a medtech innovation briefing (MIB) on PIUR tUS for abdominal aortic aneurysm surveillance and endovascular aneurysm repair endoleak detection .
NICE has developed a medtech innovation briefing (MIB) on eXroid for internal haemorrhoids .
Visensia for early detection of deteriorating vital signs in adults in hospital (MIB36)
NICE has developed a medtech innovation briefing (MIB) on Visensia for early detection of deteriorating vital signs in adults in hospital
Asfotase alfa for treating paediatric-onset hypophosphatasia (HST23)
Evidence-based recommendations on asfotase alfa (Strensiq) for treating paediatric-onset hypophosphatasia in babies, children, young people and adults.
Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma (TA818)
Evidence-based recommendations on nivolumab (Opdivo) with ipilimumab (Yervoy) for untreated unresectable malignant pleural mesothelioma in adults.
Fenfluramine for treating seizures associated with Dravet syndrome (TA808)
Evidence-based recommendations on fenfluramine (Fintepla) for treating seizures associated with Dravet syndrome in people aged 2 and older.
Dupilumab for treating severe chronic rhinosinusitis with nasal polyps (TA1134)
Evidence-based recommendations on dupilumab (Dupixent) for treating severe chronic rhinosinusitis with nasal polyps in adults.
tohelping people develop greater resilience. This is especially important if new approaches to servicedelivery, such as personalisation,...
benefit in routine care. This question should be answered by developing a new method and subsequent data analysis of existing datasets...
explanatory notes(if applicable) Why this is important:- Hevylite is a new assay that some studies have indicated is a useful prognostic...
Integrated health and social care for people experiencing homelessness (NG214)
This guideline covers providing integrated health and social care services for people experiencing homelessness. It aims to improve access to and engagement with health and social care, and ensure care is coordinated across different services.
Evidence-based recommendations on relugolix–estradiol–norethisterone acetate (Ryeqo) for treating moderate to severe symptoms of uterine fibroids in adults of reproductive age.
Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy (TA352)
Evidence-based recommendations on vedolizumab (Entyvio) for previously treated moderately to severely active Crohn’s disease in adults.
Evidence-based recommendations on eribulin (Halaven) for locally advanced or metastatic (secondary) breast cancer in adults who have had 2 or more courses of chemotherapy.
Evidence-based recommendations on rituximab (MabThera) with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis in adults.
Evidence-based recommendations on cetuximab (Erbitux), bevacizumab (Avastin) and panitumumab (Vectibix) for treating metastatic colorectal cancer in adults.
strategies). The committee were unaware of existing questionnaires and so new research should develop and test questionnaires for people...
Evidence-based recommendations on CorVue (Abbott Medical), HeartInsight (Biotronik), HeartLogic (Boston Scientific) and TriageHF (Medtronic) for algorithm-based remote monitoring in people with cardiac implantable electronic devices.
Robot-assisted surgery for orthopaedic procedures: early value assessment (HTG743)
Early value assessment (EVA) guidance on robot-assisted surgery for orthopaedic procedures.
Pulmonary artery pressure technologies for remote monitoring of chronic heart failure (HTG769)
Evidence-based recommendation on the routine use of pulmonary artery pressure technologies for remote monitoring of chronic heart failure.
Avatrombopag for treating primary chronic immune thrombocytopenia (TA853)
Evidence-based recommendations on avatrombopag (Doptelet) for treating primary chronic immune thrombocytopenia in adults.
Evidence-based recommendations on erdafitinib (Balversa) for treating unresectable or metastatic urothelial cancer with FGFR3 alterations after a PD-1 or PD-L1 inhibitor in adults.
Show all sections
Evidence-based recommendations on pembrolizumab (Keytruda) plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer in adults.
Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C (TA106)
Evidence-based recommendations on peginterferon alfa (Pegasys) and ribavirin for people with mild chronic hepatitis C.
Apixaban for preventing venous thromboembolism after hip or knee replacement surgery (TA245)
Evidence-based recommendations on apixaban (Eliquis) for preventing venous thromboembolism after hip or knee replacement in adults.
View recommendations for TA245Show all sections
and the factors that architects should take into account when designing new hospitals. Source guidance details Comes from guidance Falls
This guideline covers organising and delivering end of life care services, which provide care and support in the final weeks and months of life (or for some conditions, years), and the planning and preparation for this. It aims to ensure that people have access to the care that they want and need in all care settings. It also includes advice on services for carers.
This guideline covers preventing and managing foot problems in children, young people and adults with diabetes. It aims to reduce variation in practice, including antibiotic prescribing for diabetic foot infections.
relapsing-remitting nature of Crohn's disease with perianal fistulas. The new evidence submitted after consultation did not clarify the...
relapsing-remitting nature of Crohn's disease with perianal fistulas. The new evidence submitted after consultation did not clarify the...
to) the services. Identifying existing practice and provision will allow new drug misuse prevention activities to be compared with...